Literature DB >> 8889059

Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.

H Dichtelmüller1, D Rudnick, B Breuer, R Kotitschke, M Kloft, A Darling, E Watson, B Flehmig, S Lawson, G Frösner.   

Abstract

In order to increase the virus safety of a solvent/detergent-treated Factor VIII concentrate in regard to non-lipid coated viruses and to respond to the continuous discussion about reports on hepatitis A transmission by Factor VIII preparations, we have investigated the effect of a terminal dry heat treatment (30 min 100 degrees C) on HAV and various other viruses. By this treatment Hepatitis A virus was inactivated below detectable level after a few minutes (> 5.3 log10). Other RNA viruses such as the Human Immunodeficiency Virus (> 6.6 log10), bovine viral diarrhoea virus (> 6.6 log10) and vesicular stomatitis virus (> 5.8 log10) were also inactivated below detectable level. Pseudo rabies virus and reovirus Type 3 are inactivated by 5.7 and > 6.0 log10, respectively. SV40 and bovine parvo virus showed significant resistance to dry heat treatment. We conclude that the involvement of two strong virus inactivation steps, acting by different mechanisms, improves the virus safety of Factor VIII concentrates without destroying the Factor VIII activity. Moreover, the terminal 100 degrees C heat treatment for 30 min represents an effective measure to inactivate non-lipid enveloped viruses, in particular hepatitis A, which is resistant to solvent/detergent treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8889059     DOI: 10.1006/biol.1996.0016

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  3 in total

1.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

2.  Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins.

Authors:  Ran Zichel; Wanida Chearwae; Gouri Shankar Pandey; Basil Golding; Zuben E Sauna
Journal:  PLoS One       Date:  2012-02-27       Impact factor: 3.240

3.  Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies.

Authors:  Herbert O Dichtelmüller; Lothar Biesert; Fabrizio Fabbrizzi; Rodrigo Gajardo; Albrecht Gröner; Ilka von Hoegen; Juan I Jorquera; Christoph Kempf; Thomas R Kreil; Dominique Pifat; Wendy Osheroff; Gerhard Poelsler
Journal:  Transfusion       Date:  2009-05-20       Impact factor: 3.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.